Evidence map›Paper›PMID 30518093›Full record

ReviewInternational journal of molecular sciences2018

Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells.

Takayasu Mishima, Shinsuke Fujioka, Jiro Fukae, Junichi Yuasa-Kawada, Yoshio Tsuboi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation.International journal of molecular sciences · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takayasu MishimaDepartment of Neurology, Fukuoka University, Fukuoka 814-0180, Japan. mishima1006@fukuoka-u.ac.jp.
Shinsuke FujiokaDepartment of Neurology, Fukuoka University, Fukuoka 814-0180, Japan. shinsuke@cis.fukuoka-u.ac.jp.
Jiro FukaeDepartment of Neurology, Fukuoka University, Fukuoka 814-0180, Japan. j-fukae@juntendo.ac.jp.
Junichi Yuasa-KawadaDepartment of Neurology, Fukuoka University, Fukuoka 814-0180, Japan. junkichi@marine.email.ne.jp.
Yoshio TsuboiDepartment of Neurology, Fukuoka University, Fukuoka 814-0180, Japan. tsuboi@cis.fukuoka-u.ac.jp.
Fukuoka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) and atypical parkinsonian syndromes are age-dependent multifactorial neurodegenerative diseases, which are clinically characterized by bradykinesia, tremor, muscle rigidity and postural instability. Although these diseases share several common clinical phenotypes, their pathophysiological aspects vary among the disease categories. Extensive animal-based approaches, as well as postmortem studies, have provided important insights into the disease mechanisms and potential therapeutic targets. However, the exact pathological mechanisms triggering such diseases still remain elusive. Furthermore, the effects of drugs observed in animal models are not always reproduced in human clinical trials. By using induced pluripotent stem cell (iPSC) technology, it has become possible to establish patient-specific iPSCs from their somatic cells and to effectively differentiate these iPSCs into different types of neurons, reproducing some key aspects of the disease phenotypes in vitro. In this review, we summarize recent findings from iPSC-based modeling of PD and several atypical parkinsonian syndromes including multiple system atrophy, frontotemporal dementia and parkinsonism linked to chromosome 17 and Perry syndrome. Furthermore, we discuss future challenges and prospects for modeling and understanding PD and atypical parkinsonian syndromes.

Indexed as

Models, BiologicalAgingAnimalsCell- and Tissue-Based TherapyGene EditingHumansInduced Pluripotent Stem CellsParkinson Diseaseatypical parkinsonian syndromesCRISPRFTDP-17induced pluripotent stem cellsmultiple system atrophyParkinson’s diseasePerry syndromeproteinopathy

Identifiers

PMID30518093
PMCPMC6321610
OpenAlexW2902868220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.